Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Learn more about whether Alvotech or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Full Year 2024 Results Key Financial Results Revenue: US$492.0m (up 427% from FY 2023).

Learn more about whether Alvotech or Merus N.V. is a better investment based on AAII's A+ Investor grades, which compare both ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

It's been a mediocre week for Alvotech (NASDAQ:ALVO) shareholders, with the stock dropping 17% to US$9.55 in the week since its latest yearly results. The results don't look great, especially ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a ...

It's been a mediocre week for Alvotech ( NASDAQ:ALVO ) shareholders, with the stock dropping 17% to US$9.55 in the ...

Alvotech (NASDAQ:ALVOW – Get Free Report) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 6,000 shares, a decline of 36.2% from ...

Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00.